stockrowNatera, Inc.
NTRA Healthcare Diagnostics & Research
Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024.
- Revenue
- +34.1%
- EPS
- +34.4%
- Free cash flow
- −85.8%
- Total debt
- −0.06%
Quarter to September 2026, against a year earlier
Follow NTRA
Alert me
Natera, Inc. (NTRA) Return on assets
Natera, Inc.'s return on assets over the twelve months to 30 September 2026 was −7.21%, up 3.0 percentage points from fiscal 2025 (−10.3%). Over the past ten years it has ranged from −64.7% (fiscal 2017) to −10.3% (fiscal 2025) — the current reading is the highest in ten years. That is below the Diagnostics & Research industry median of −6.05% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −10.3% | 2.02 |
| FY2024 | −12.3% | 18.38 |
| FY2023 | −30.7% | 10.98 |
| FY2022 | −41.6% | 1.86 |
| FY2021 | −43.5% | (13.17) |
| FY2020 | −30.3% | (0.99) |
| FY2019 | −29.3% | 23.75 |
| FY2018 | −53.1% | 11.63 |
| FY2017 | −64.7% | (22.56) |
| FY2016 | −42.2% | (6.02) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| IDXX IDEXX Laboratories, Inc. compare | 33.3% |
| MTD Mettler-Toledo International, Inc. compare | 25.6% |
| ILMN Illumina, Inc. compare | 13.8% |
| A Agilent Technologies, Inc. compare | 11.0% |
| DGX Quest Diagnostics Incorporated compare | 6.73% |
| LH Labcorp Holdings Inc. compare | 5.40% |
| IQV IQVIA Holdings Inc. compare | 4.71% |
| WAT Waters Corporation compare | 0.68% |
| NTRA Natera, Inc. | −7.21% |
| Diagnostics & Research industry median | −6.05% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on NTRA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement